BNET Industries

Last Fiscal Year Sales:$52.2M
  • Public
  • US
Dow Jones Description

AtheroGenics is a research-based pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. We currently have one late stage clinical drug development program. On September 15, 2008, an involuntary petition under Chapter 7 of the United States Bankruptcy Code (the "Bankruptcy Code") was filed against us by certain holders of our 4.5% Convertible Notes Due 2008 (the "2008 Notes") in the United States Bankruptcy Court for the Northern District of Georgia (the "Bankruptcy Court"). On October 6, 2008, we consented to the bankruptcy filing and moved the Bankruptcy Court to convert the Chapter 7 case to a case under Chapter 11 of the United States Bankruptcy Code (the "Chapter 11 Proceeding"). This motion was granted on October 15, 2008. No trustee, receiver or examiner has been appointed, and we expect to act as debtor-in-possession while being subject to the supervision and order of the Bankruptcy Court. ...

Chief Executive Officer
Russell M. Medford
Number of Employees 57
Contact Information

8995 Westside Pkwy

Alpharetta, Georgia 30004-4777

atherogenics.co...

(678) 336-2500

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

News & Analysis

atherogenics inc. and stock - All News and Analysis

Decision Makers

Name (plus bio) Position
Russell M. Medford Chief Executive Officer
Charles A. Deignan President, Chief Financial Officer and Secretary
David M Stern Dean, School of Medicine, Chief Clinical Officer, Professor of Medicine
Mark P. Colonnese Chief Financial Officer
Peter Libby Chief, Cardiovascular Division Department of Medicine, Brigham
Robert A D Scott Executive Vice President, Research and Development and Chief Medical Officer
Joseph M. Gaynor General Counsel, Secretary & Senior Vice President
M Joseph Jr Senior Vice President & General Counsel
W. Charles Montgomery Senior Vice President, Business Development and Alliance Management
William Charles Montgomery Senior Vice President Business Development
R. Wayne Alexander Scientific Co-Founder
Charles Montgomery
Michael A. Henos Executive Compensation
Roger D Kitterman

Board of Directors

Name (plus bio) Position
David Bearman Chairman
Erwin W Gelfand Chairman, Department of Pediatrics, National Jewish Medical and Research Center
Gary L Johnson Professor and Chairman, Department of Pharmacology
David G Harrison Board of Directors
Margaret E. Grayson Board of Directors
Samuel L. Barker Board of Directors
Stephen G. Sudovar Board of Directors
Victor J. Dzau Board of Directors
William W Busse Board of Directors

Dr. Medford previously served as President and Chief Executive Officer of AtheroGenics, Inc., an Atlanta-based company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases. He is a member of the Board of Directors for the Biotechnology Industry Organization (BIO).

Organization Position Status
AtheroGenics, Inc. Chief Executive Officer Current
Georgia Biomedical Partnership President and CEO, Atherogenics Current
AtheroGenics, Inc. President Current
Georgia Biomedical Partnership Chairman Current
The National Health Museum, Inc Board of Directors Current
Inhibitex, Inc. Director Current
Informed Horizons, LLC Board of Directors Current
Emory University School of Medicine Director of Molecular Cardiology Former
Emory University School of Medicine Associate Professor of Medicine Former
Georgia Biomedical Partnership Vice Chairman of the Board of Directors Current
Albert Einstein College of Medicine Ph.D. in molecular and cell biology Former
Albert Einstein College M.D. Former
Cornell University B.A. Former

Charles A. Deignan has served as President, Chief Financial Officer and Secretary of AtheroGenics since his appointment on April 1, 2009. From January 2007 and until his most recent appointment, Mr. Deignan previously served as AtheroGenics Vice President of Finance and Administration and Principal Accounting Officer. Mr. Deignan is AtheroGenics only executive officer, and will oversee the wind down of the Chapter 11 Proceeding.

Organization Position Status
AtheroGenics, Inc. President, Chief Financial Officer and Secretary Current
AtheroGenics, Inc. Secretary Current
AtheroGenics, Inc. Principal Accounting Officer, Vice President, Finance & Admin Former
AtheroGenics, Inc. Assistant Secretary & Senior Director, Finance & Admin Former

Organization Position Status
AtheroGenics, Inc. Dean, School of Medicine, Chief Clinical Officer, Professor of Medicine Current
AtheroGenics, Inc. Dean Current
Medical College of Georgia Dean Current
AtheroGenics, Inc. Board of Directors Current

Organization Position Status
AtheroGenics, Inc. Chief Financial Officer Current
AtheroGenics, Inc. Executive Vice President, Commercial Operations Current
Fairleigh Dickinson University M.B.A. Former
Ithaca College B.S. Former

Organization Position Status
AtheroGenics, Inc. Chief, Cardiovascular Division Department of Medicine, Brigham Current
Braunwald's Heart Disease Chief of Cardiovascular Medicine at the Brigham and Women's Hospital Current
The Women's Hospital Chief of Cardiovascular Medicine Current
Harvard Medical School Mallinckrodt Professor of Medicine Current
Braunwald's Heart Disease Co-Editor Current
Recordati Corporation Current
Cardiometabolic Health Congress Current
Cardiovascular Protection Alliance (CPA) Chair Current
Cardiology Today Board of Directors Current
AtheroGenics, Inc. Board of Directors Current
Interleukin Genetics, Inc. Board of Directors Current
Columbia University Professor of Clinical Medicine Former
American Heart Association, Inc. Volunteer Former
Circulation, Inc. Associate Former
Circulation, Inc. Consulting Editor Former
University of California, San Diego School of Medicine M.D. Former
University of California, San Diego MD Former
Harvard University Master of Arts Degree Former
University of California, Berkeley BA Former
University of California, San Diego Degree Former

Organization Position Status
AtheroGenics, Inc. Executive Vice President, Research and Development and Chief Medical Officer Current
Janssen Pharmaceutica Medical Advisor Former

Organization Position Status
AtheroGenics, Inc. General Counsel, Secretary & Senior Vice President Current
Lanier Worldwide, Inc. Legal Counsel Former
Emory University law degree Former
Miami University B.S. In Accounting and Finance Former
Emory University School of Law Degree Former

Organization Position Status
AtheroGenics, Inc. Senior Vice President & General Counsel Current

Organization Position Status
AtheroGenics, Inc. Senior Vice President, Business Development and Alliance Management Current
University of Minnesota Ph.D. In Organic Chemistry Former
Southern Methodist University B.S. In Chemistry Former

Organization Position Status
AtheroGenics, Inc. Senior Vice President Business Development Current
University of Minnesota Ph.D. In Organic Chemistry Former
Southern Methodist University B.S. In Chemistry Former

R. Wayne Alexander, MD, PhD (Chairman) - Dr. Alexander is R. Bruce Logue Professor of Medicine, and Chairman, Department of Medicine, for Emory University School of Medicine, Atlanta, Georgia. Dr. Alexander received his PhD in physiology from Emory University and his MD from Duke University School of Medicine. He completed his residency in internal medicine at the University of Washington, Seattle, and did his fellowship in cardiology at Duke University. Prior to his appointment at Emory, Dr. Alexander was Associate Professor of Medicine at Harvard Medical School. Dr. Alexander has published extensively in the cardiovascular literature. In addition, he is coeditor of Hurst's The Heart, 8th edition and Companion Handbook of The Heart, 8th edition. He is on the editorial boards of many journals including the Journal of Clinical Investigation, Circulation Research, and Circulation. Active in many professional societies, Dr. Alexander is a member of the American Heart Association, the American College of Cardiology, the American Federation for Medical Research, and Federation of American Societies for Experimental Biology. His research interests include the biologic basis of the pathogenesis of the coronary ischemic syndromes, the molecular mechanisms of hormonal control of vascular reactivity and the cell biology of vascular smooth muscle and endothelium.

Organization Position Status
AtheroGenics, Inc. Scientific Co-Founder Current
Pappas & Associates Selector Current
AtheroGenics, Inc. Chairman, Department of Medicine, Emory University School of Medicine Current
American Heart Association, Inc. Board of Directors Current
AtheroGenics, Inc. Director Current
American College of Cardiology Board of Directors Current
American Federation for Medical Research Board of Directors Current
American College of Cardiology Member Current
American Heart Association, Inc. Member Current
American Federation for Medical Research Member Current
Harvard Medical School Associate Professor of Medicine Former
Emory University School of Medicine Professor Former
Emory University School of Medicine Chairman Former
Emory University PhD In Physiology Former
Duke University MD Former
Duke University School of Medicine M.D. Former

Organization Position Status
AtheroGenics, Inc. Current
Celera Genomics Vice President of Business Development and Portfolio Planning Former
University of Minnesota Ph.D., Organic Chemistry Former
Southern Methodist University B.S. in Chemistry Former

Organization Position Status
Alliance Technology Ventures Founder Current
Alliance Technology Ventures Managing General Partner Current
AtheroGenics, Inc. Executive Compensation Current
Inhibitex, Inc. Chairman of the Board Current
Glycomimetics, Inc. Director Current
Genoptix, Inc. Director Current
Neuronyx Board of Directors Current
Aderis Pharmaceuticals, Inc. Investor Current
3i Ventures Corporation Vice President Former
The Ventures Vice President Former
Alliance Technology Ventures Managing Director Former
Aspen Ventures General Partner Former
Ernst & Young Health Care Consultant Former
Adeza Biomedical Corporation Investor Former
Inhibitex, Inc. Investor Former
Ligand Pharmaceuticals Incorporated Investor Former
RF Micro Devices, Inc. Investor Former
Amylin Pharmaceuticals, Inc. Investor Former
AtheroGenics, Inc. Investor Former
University of California MBA Former
University of California, Los Angeles MBA Former
University of California, Los Angeles BS In Economics Former
University of California BS in economics Former

Roger Kitterman joined Mi3 Venture Partners in 2003. Roger is an experienced venture capital investor and has guided multiple venture-backed companies through the earliest stages of development. He represents Mi3 on the Board of FlowMedica. Roger has over ten years of venture capital experience investing in healthcare companies. He has also been the startup CEO for three venture-backed companies. Prior to joining Mi3, he was a managing director at Lee Munder Venture Partners, the venture capital arm of Lee Munder Capital Group. He joined Lee Munder from Boston University's Community Technology Fund, where he made venture capital investments in the life sciences and developed spinouts from the university. Roger began his venture capital career in Eastern Europe with the Bulgarian-American Enterprise Fund, a $55 million venture capital fund. Roger's track record includes investments in AtheroGenics (NASDAQ: AGIX), Exact Sciences (NASDAQ: EXAS), NitroMed (NASDAQ: NTMD), and Sequenom (NASDAQ: SQNM). Roger received his M.B.A. (Finance and Business Development) from the Columbia School of Business and his B.A. from Harvard College.

Organization Position Status
MI3 Venture Partners General Partner Current
EXACT Sciences Corporation Current
NitroMed, Inc. Current
AtheroGenics, Inc. Current
Sequenom, Inc. Current
Lee Munder Capital Group Managing Director Former
Harvard College B.A. Former

Organization Position Status
Home Depot Supply CFO & Executive Vice President, Operations Current
AtheroGenics, Inc. Chairman Current
Home Depot Supply Board of Directors Current
NCR Corporation Chief Financial Officer Former
Cardinal Health, Inc. Chief Financial Officer Former
NCR Corporation Senior Vice President Former

Organization Position Status
International Archives Associate Editor Current
AtheroGenics, Inc. Chairman, Department of Pediatrics, National Jewish Medical and Research Center Current
National Jewish Medical and Research Center Chairman of the Department of Pediatrics Current
American Academy of Allergy Asthma & Immunology Board of Directors Current
Clinical Immunology Society Board of Directors Current
American Academy of Allergy Asthma & Immunology Member Current
Clinical Immunology Society Member Current
McGill University Degree Former

Organization Position Status
AtheroGenics, Inc. Professor and Chairman, Department of Pharmacology Current
American Heart Association, Inc. Established Investigator Former

Organization Position Status
AtheroGenics, Inc. Board of Directors Current

Margaret E. (Peg) Grayson was elected to the AtheroGenics board of directors in July 2006. Ms. Grayson is President of Coalescent Technologies, a professional engineering firm that provides engineering products and services to the Department of Defense, federal agencies and commercial clients. She is also the President of Grayson & Associates, a management consulting and advisory practice for audit, policy and regulatory compliance. From 2005 until 2006, Ms. Grayson served as President of AEP Government Solutions Group and Executive Vice President and General Manager of AEP Networks. She served as President and CEO of V-ONE Corporation, before it combined with AEP Networks in 2005. Prior to joining V-ONE, Ms. Grayson served as Chief Financial Officer for SPACEHAB, Inc., and for Sirius Satellite Radio, dba, CD Radio, Inc. in Washington, D.C. She is a member of the National Infrastructure Advisory Council (NIAC), serving at the request of President George W. Bush, and provides advice to the Secretary of Homeland Security and the President on the security of our Nation s critical infrastructure. Ms. Grayson is a member of the Financial Executives Institute of Washington D.C., the Potomac Officers Club and has been named to Maryland s Top 100 Women. She is a member of the Dean s Advisory Council for the School of Management at the State University of New York, and the Advisory Board for the Center of Excellence in Information Assurance at SUNY Buffalo. Ms. Grayson holds an M.B.A. from the University of South Florida and a B.S. in Accounting from the State University of New York at Buffalo.

Organization Position Status
Coalescent Technologies Corporation President Current
Grayson & Associates, Inc. President Current
Hartwick College Assistant Professor of Finance and Accounting Current
AtheroGenics, Inc. Board of Directors Current
Aep Networks, Inc. CEO Former
SIRIUS Satellite Radio Inc. Chief Financial Officer Former
Aep Networks, Inc. Executive Vice President Former
Aep Networks, Inc. General Manager Former
V One Corp Former
University of South Florida M.B.A. Former
State University of New York at Buffalo B.S. In Accounting Former

Organization Position Status
Clearview Projects, Inc Founder Current
Lexicon Pharmaceuticals, Inc. Chairman Current
The Cancer Institute of New Jersey Board of Directors Current
Cadence Pharmaceuticals, Inc. Board of Directors Current
AtheroGenics, Inc. Board of Directors Current
Symphony Capital LLC Board of Directors Current
Clearview Projects, Inc CEO Former
Clearview Projects, Inc President Former
Bristol-Myers Squibb Company President Former
Lexicon Genetics Incorporated Chairman Former
Lexicon Genetics Incorporated Director Former
Purdue University Ph.D. Former
University of Arkansas M.S. Former
Purdue University B.S. Former
Purdue University Degrees Former

Organization Position Status
AtheroGenics, Inc. Board of Directors Current

Organization Position Status
Duke University Health System Chief Executive Officer Current
Duke University Chief Executive Officer, Health System & Chancellor, Health Affairs Current
Kearny Venture Partners Senior Advisor Current
Bristol-Myers Squibb Company Consultant Current
Merck & Co. Inc. Consultant Current
Novartis AG Consultant Current
Tengion, Inc. Current
PepsiCo, Inc. Board of Directors Current
AtheroGenics, Inc. Board of Directors Current
Alnylam Pharmaceuticals, Inc. Board of Directors Current
Medtronic, Inc. Board of Directors Current
Hypertension Online Board of Directors Current
Genzyme Corporation Board of Directors Current
National Academy of Sciences Member Current
European Academy of Sciences Member Current
Duke University President Former
Brigham & Women's Hospital Physician in Chief & Director of Research Former
Harvard Medical School Hersey Professor, Theory and Practice of Physic (Medicine) Former
Stanford University Professor Former
National Institutes of Health Chairman Former
Harvard Medical School Chairman, Department of Medicine Former
Bg Medicine, Inc. Board of Directors Former
Harvard Medical School Postgraduate Training Former
McGill University MD Former

Organization Position Status
University of Wisconsin Medical School Head Current
Pulmicort Current
Exchange: Airway Disease Understanding Exchange Program Chairman Current
Department of Medicine Chair Current
Innovia Education Institute, LLC. Board of Directors Current
AtheroGenics, Inc. Board of Directors Current
Altair Therapeutics, Inc. Board of Directors Current
Aaaai Fellow Current
American Academy of Allergy Asthma & Immunology President Former
Aaaai President Former
American Academy of Allergy Asthma & Immunology Board of Directors Former
University of Wisconsin Medical School Degree Former

Executive News

  • Akebia Appoints Victor Dzau, M.D. to Board of Directors

    Market Wire - 9/01/09 - View Story

advertisement
advertisement